Medlab ME is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Medlab ME is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

DiaSys Announces Essential Product Launches

New enzymatic test for HbA1c 

The worldwide rapid rise in diabetes is a challenge for treatment as well as for diagnosis and monitoring. With the new test HbA1c net FS, DiaSys has introduced an innovative product with highest accuracy setting new standards for reliable results in diagnosing and monitoring diabetes. Based on enzymatic measurement Hba1c net FS ensures highest specificity without interferences by haemoglobin variants or other substances in blood as well as outstanding precision. In combination with the DiaSys analysers BioMajesty® JCA-BM 6010/C and respons®910, labs of every size can optimize their workflow for HbA1c due to the fully automated process including on-board haemolysis.

Besides this crucial product launch, other major achievements were made in time for DiaSys’ 25th anniversary in 2016. Under the trademark QDx, DiaSys announced a point-of-care product line comprising test strips and devices for various diagnostic fields such as cardiac, vitamin D, allergy, anaemia, lipids, mosquito-borne diseases or urinalysis. The first new product in 2017 will be the high-performance test Acetaminophen FS. The recently founded subsidiary DiaSys USA introduced the respons®910VET analyser as versatile solution for the veterinarian lab. Furthermore, respons®910UP was introduced; this upgraded version of DiaSys’ fully-automated analyser for the small clinical lab offers improved handling and performance and lead to boosting sales establishing DiaSys as player in the systems market.

For 25 years, DiaSys Diagnostic Systems has been successful as mid-size company in the challenging and ever changing market of in vitro diagnostics; and represents special know-how in development and manufacturing of diagnostic system solutions of high quality. Focusing on clinical chemistry and immunoturbidimetric tests, DiaSys has introduced more than 90 optimized reagents for routine and special diagnostics. The instrument range comprises automated clinical chemistry analysers for small to mid-size labs. The product portfolio also includes a point-of-care line and a broad range of quality control material. To date, customers and partners in more than 100 countries around the world rely on DiaSys quality.